Xponance Inc. Boosts Holdings in Insulet Co. (NASDAQ:PODD)

Xponance Inc. raised its position in shares of Insulet Co. (NASDAQ:PODD) by 1.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,861 shares of the medical instruments supplier’s stock after purchasing an additional 250 shares during the quarter. Xponance Inc.’s holdings in Insulet were worth $3,201,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sunbelt Securities Inc. purchased a new position in Insulet in the 1st quarter worth approximately $29,000. International Assets Investment Management LLC purchased a new position in shares of Insulet in the second quarter worth $32,000. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Insulet during the fourth quarter valued at $40,000. Finally, CVA Family Office LLC increased its holdings in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group raised their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Redburn Atlantic began coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 target price for the company. BTIG Research dropped their price target on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Canaccord Genuity Group upped their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $231.71.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $238.80 on Thursday. The firm’s 50 day simple moving average is $205.26 and its two-hundred day simple moving average is $189.69. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The company has a market capitalization of $16.74 billion, a P/E ratio of 72.36, a P/E/G ratio of 4.47 and a beta of 1.21. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $243.98.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing the consensus estimate of $0.56 by ($0.01). The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.38 EPS. Research analysts expect that Insulet Co. will post 3.04 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.